Poseida Therapeutics, Inc.
PSTX · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 176.2% | -7.7% | 12.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 94.8% | 95.1% | 83.3% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 33.3% | -106.9% | -73.3% | -86.6% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 28.2% | -120.8% | -86.3% | -96% |
| EPS Diluted | 0.21 | -0.32 | -0.25 | -0.27 |
| % Growth | 165.6% | -28% | 7.4% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | -$0 | -$0 |